MARKET

CING

CING

Cingulate Inc
NASDAQ
7.70
+1.21
+18.64%
After Hours: 7.74 +0.04 +0.47% 19:59 02/06 EST
OPEN
6.75
PREV CLOSE
6.49
HIGH
7.75
LOW
6.53
VOLUME
535.66K
TURNOVER
--
52 WEEK HIGH
7.75
52 WEEK LOW
3.200
MARKET CAP
73.05M
P/E (TTM)
-1.4396
1D
5D
1M
3M
1Y
5Y
1D
Cingulate Advances Capital Raise with Private Placement Financing
TipRanks · 1d ago
Cingulate Inc. Raises $6.5 Million in Private Placement of Unregistered Shares
Reuters · 1d ago
Weekly Report: what happened at CING last week (0126-0130)?
Weekly Report · 6d ago
CINGULATE: ENTERS SECURITIES PURCHASE AGREEMENT FOR PRIVATE PLACEMENT; INCLUDES 2.14 MLN COMMON SHARES AND 973 PREFERRED SHARES - SEC FILING
Reuters · 01/28 21:33
Cingulate Announces Private Placement and New Preferred Stock
TipRanks · 01/28 21:32
Weekly Report: what happened at CING last week (0119-0123)?
Weekly Report · 01/26 10:29
Biotech Sector Sees Broad After-Hours Gains Amid Quiet News Flow
NASDAQ · 01/23 04:42
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 01/22 12:05
More
About CING
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.

Webull offers Cingulate Inc stock information, including NASDAQ: CING real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CING stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CING stock methods without spending real money on the virtual paper trading platform.